{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:34:18Z","timestamp":1771652058132,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/51994\/2012"],"award-info":[{"award-number":["SFRH\/BD\/51994\/2012"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10637-019-00796-2","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T04:59:14Z","timestamp":1559278754000},"page":"369-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines"],"prefix":"10.1007","volume":"38","author":[{"given":"Joana","family":"Jorge","sequence":"first","affiliation":[]},{"given":"Sara","family":"Petronilho","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Coucelo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1470-4802","authenticated-orcid":false,"given":"Ana Cristina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Manuel","family":"Nascimento Costa","sequence":"additional","affiliation":[]},{"given":"Ana Bela","family":"Sarmento-Ribeiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"796_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbior.2016.08.001","volume":"63","author":"A Pellagatti","year":"2016","unstructured":"Pellagatti A, Boultwood J (2016) Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications. Adv Biol Regul 63:59\u201370. https:\/\/doi.org\/10.1016\/j.jbior.2016.08.001","journal-title":"Adv Biol Regul"},{"issue":"9","key":"796_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/nm.4165","volume":"22","author":"SCW Lee","year":"2016","unstructured":"Lee SCW, Abdel-Wahab O (2016) Therapeutic targeting of slicing in cancer. Nat Med 22(9):976\u2013986. https:\/\/doi.org\/10.1038\/nm.4165","journal-title":"Nat Med"},{"issue":"9","key":"796_CR3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.celrep.2017.08.012","volume":"20","author":"H Climente-Gonz\u00e1lez","year":"2017","unstructured":"Climente-Gonz\u00e1lez H, Porta-Pardo E, Godzik A, Eyras E (2017) The functional impact of alternative splicing in Cancer. Cell Rep 20(9):2215\u20132226. https:\/\/doi.org\/10.1016\/j.celrep.2017.08.012","journal-title":"Cell Rep"},{"issue":"7367","key":"796_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 478(7367):64\u201369. https:\/\/doi.org\/10.1038\/nature10496","journal-title":"Nature."},{"issue":"15","key":"796_CR5","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J et al (2011) For the chronic myeloid disorders working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365(15):1384\u20131395. https:\/\/doi.org\/10.1056\/NEJMoa1103283","journal-title":"N Engl J Med"},{"issue":"14","key":"796_CR6","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1182\/blood-2011-12-399774","volume":"119","author":"H Makishima","year":"2012","unstructured":"Makishima H, Visconte V, Sakaguchi H et al (2012) Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 119(14):3203\u20133210. https:\/\/doi.org\/10.1182\/blood-2011-12-399774","journal-title":"Blood."},{"key":"796_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau DA, Carter SL, Stojanov P et al (2013) Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 152:714\u2013726. https:\/\/doi.org\/10.1016\/j.cell.2013.01.019","journal-title":"Cell."},{"issue":"9","key":"796_CR8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 125(9):1367\u20131376. https:\/\/doi.org\/10.1182\/blood-2014-11-610543","journal-title":"Blood."},{"issue":"8","key":"796_CR9","doi-asserted-by":"publisher","first-page":"9084","DOI":"10.18632\/oncotarget.7000","volume":"7","author":"HA Hou","year":"2016","unstructured":"Hou HA, Liu CY, Kuo YY et al (2016) Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia. Oncotarget. 7(8):9084\u20139101. https:\/\/doi.org\/10.18632\/oncotarget.7000","journal-title":"Oncotarget."},{"issue":"1","key":"796_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/cas.12317","volume":"105","author":"M Sato","year":"2014","unstructured":"Sato M, Muguruma N, Nakagawa T et al (2014) High antitumor activity of pladienolide B and its derivative in gastric cancer. Cancer Sci 105(1):110\u2013116. https:\/\/doi.org\/10.1111\/cas.12317","journal-title":"Cancer Sci"},{"issue":"24","key":"796_CR11","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1111\/j.1742-4658.2011.08387.x","volume":"278","author":"A Yokoi","year":"2011","unstructured":"Yokoi A, Kotake Y, Takahashi K et al (2011) Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J 278(24):4870\u20134880. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08387.x","journal-title":"FEBS J"},{"issue":"2","key":"796_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172209","volume":"12","author":"K Suda","year":"2017","unstructured":"Suda K, Rozeboom L, Yu H et al (2017) Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS One 12(2):e0172209. https:\/\/doi.org\/10.1371\/journal.pone.0172209","journal-title":"PLoS One"},{"issue":"3","key":"796_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.7164\/antibiotics.57.188","volume":"57","author":"Y Mizui","year":"2004","unstructured":"Mizui Y, Sakai T, Iwata M et al (2004) Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. J Antibiot 57(3):188\u2013196. https:\/\/doi.org\/10.7164\/antibiotics.57.188","journal-title":"J Antibiot"},{"issue":"7","key":"796_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3324\/haematol.2014.122069","volume":"100","author":"MK Kashyap","year":"2015","unstructured":"Kashyap MK, Kumar D, Villa R et al (2015) Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica. 100(7):945\u2013954. https:\/\/doi.org\/10.3324\/haematol.2014.122069","journal-title":"Haematologica."},{"issue":"26","key":"796_CR15","doi-asserted-by":"publisher","first-page":"22734","DOI":"10.18632\/oncotarget.4212","volume":"6","author":"S Xargay-Torrent","year":"2015","unstructured":"Xargay-Torrent S, L\u00f3pez-Guerra M, Rosich L et al (2015) The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget. 6(26):22734\u201322749. https:\/\/doi.org\/10.18632\/oncotarget.4212","journal-title":"Oncotarget."},{"issue":"4","key":"796_CR16","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1074\/jbc.M113.515536","volume":"289","author":"KA Effenberger","year":"2014","unstructured":"Effenberger KA, Anderson DD, Bray WM, Prichard BE, Ma N, Adams MS, Ghosh AK, Jurica MS (2014) Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs. J Biol Chem 289(4):1938\u20131947. https:\/\/doi.org\/10.1074\/jbc.M113.515536","journal-title":"J Biol Chem"},{"issue":"33","key":"796_CR17","doi-asserted-by":"publisher","first-page":"23029","DOI":"10.18632\/oncotarget.25196","volume":"9","author":"LA Hepburn","year":"2018","unstructured":"Hepburn LA, McHugh A, Fernandes K et al (2018) Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity. Oncotarget. 9(33):23029\u201323046. https:\/\/doi.org\/10.18632\/oncotarget.25196","journal-title":"Oncotarget."},{"issue":"2","key":"796_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.blre.2017.09.002","volume":"32","author":"P Boddu","year":"2018","unstructured":"Boddu P, Benton CB, Wang W, Borthakur G, Khoury JD, Pemmaraju N (2018) Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev 32(2):96\u2013105. https:\/\/doi.org\/10.1016\/j.blre.2017.09.002","journal-title":"Blood Rev"},{"issue":"2","key":"796_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/MOH.0000000000000314","volume":"24","author":"DA Arber","year":"2017","unstructured":"Arber DA (2017) Revisiting erythroleukemia. Curr Opin Hematol 24(2):146\u2013151. https:\/\/doi.org\/10.1097\/MOH.0000000000000314","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"796_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1586\/ehm.10.62","volume":"3","author":"FPS Santos","year":"2010","unstructured":"Santos FPS, Bueso-Ramos CE, Ravandi F (2010) Acute erythroleukemia: diagnosis and management. Expert Rev Hematol 3(6):705\u2013718. https:\/\/doi.org\/10.1586\/ehm.10.62","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"796_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/sj.leu.2404081","volume":"20","author":"H Quentmeier","year":"2006","unstructured":"Quentmeier H, MacLeod RA, Zaborski M, Drexler HG (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia. 20(3):471\u2013476","journal-title":"Leukemia."},{"issue":"5","key":"796_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561\u2013566","journal-title":"Nat Med"},{"key":"796_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ebiom.2018.12.025","volume":"39","author":"R Sciarrillo","year":"2019","unstructured":"Sciarrillo R, Wojtuszkiewicz A, Hassouni BEI et al (2019) Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine. 39:215\u2013225. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.025","journal-title":"EBioMedicine."},{"issue":"4","key":"796_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/sj.leu.2403310","volume":"18","author":"S Salesse","year":"2004","unstructured":"Salesse S, Dylla SJ, Verfaillie CM (2004) p210BCR\/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia. 18(4):727\u2013733. https:\/\/doi.org\/10.1038\/sj.leu.2403310","journal-title":"Leukemia."},{"issue":"7","key":"796_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2174\/15680096113139990083","volume":"13","author":"S Adamia","year":"2013","unstructured":"Adamia S, Pilarski PM, Bar-Natan M, Stone RM, Griffin JD (2013) Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? Curr Cancer Drug Targets 13(7):735\u2013748. https:\/\/doi.org\/10.2174\/15680096113139990083","journal-title":"Curr Cancer Drug Targets"},{"key":"796_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jbior.2013.09.005","volume":"54","author":"J Boultwood","year":"2014","unstructured":"Boultwood J, Dolatshad H, Varanasi SS, Yip BH, Pellagatti A (2014) The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. Adv Biol Regul. 54:153\u2013161. https:\/\/doi.org\/10.1016\/j.jbior.2013.09.005","journal-title":"Adv Biol Regul."},{"issue":"20","key":"796_CR27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/jnci\/djt257","volume":"105","author":"LM Scott","year":"2013","unstructured":"Scott LM, Rebel VI (2013) Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. J Natl Cancer Inst 105(20):1540\u20131549. https:\/\/doi.org\/10.1093\/jnci\/djt257","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"796_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/blood-2012-09-399725","volume":"121","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Rossi M, Malcovati L (2013) Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 121(2):260\u2013269. https:\/\/doi.org\/10.1182\/blood-2012-09-399725","journal-title":"Blood."},{"issue":"12","key":"796_CR29","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/leu.2012.130","volume":"26","author":"V Visconte","year":"2012","unstructured":"Visconte V, Makishima H, Maciejewski JP, Tiu RV (2012) Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia. 26(12):2447\u20132454. https:\/\/doi.org\/10.1038\/leu.2012.130","journal-title":"Leukemia."},{"issue":"1","key":"796_CR30","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1038\/s41467-018-06063-x","volume":"9","author":"Y Shiozawa","year":"2018","unstructured":"Shiozawa Y, Malcovati L, Gall\u00ec A et al (2018) Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nat Commun 9(1):3649. https:\/\/doi.org\/10.1038\/s41467-018-06063-x","journal-title":"Nat Commun"},{"issue":"1","key":"796_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/onc.2012.38","volume":"32","author":"N Allende-Vega","year":"2013","unstructured":"Allende-Vega N, Dayal S, Agarwala U, Sparks A, Bourdon JC, Saville MK (2013) p53 is activated in response to disruption of the pre-mRNA splicing machinery. Oncogene. 32(1):1\u201314. https:\/\/doi.org\/10.1038\/onc.2012.38","journal-title":"Oncogene."},{"issue":"12","key":"796_CR32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/0145-2126(93)90161-D","volume":"17","author":"JC Law","year":"1993","unstructured":"Law JC, Ritke MK, Yalowich JC, Leder GH, Ferrell RE (1993) Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 17(12):1045\u20131050","journal-title":"Leuk Res"},{"key":"796_CR33","unstructured":"H3 Biomedicine Inc. A Phase 1 Study to evaluate H3B-8800 in participants with Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia 2016 (Clinicaltrials.gov Identifier NCT02841540) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02841540?cond=NCT02841540&rank=1"},{"issue":"15_suppl","key":"796_CR34","doi-asserted-by":"publisher","first-page":"TPS7075","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7075","volume":"35","author":"DP Steensma","year":"2017","unstructured":"Steensma DP, Maris MB, Yang J et al (2017) H3B-8800-G0001-101: a first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies. J Clin Oncol 35(15_suppl):TPS7075. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.TPS7075","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00796-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00796-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00796-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:44:30Z","timestamp":1678560270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00796-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["796"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00796-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"17 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Studies of animal models were not performed. This article does not contain any studies with human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}